27.07.2026

Treatment for AMD: what’s available today to preserve your sight

There is as yet no complete cure for AMD, but effective treatments are now available to slow its progression and preserve vision. The key is early diagnosis and regular monitoring.

For wet AMD: anti-VEGF injections

The exudative form of AMD can be treated effectively with intravitreal injections of anti-VEGF drugs. These injections, administered directly into the eye by a specialist ophthalmologist, block the growth of abnormal blood vessels and prevent the build-up of fluid beneath the retina. When administered at regular intervals, they can, in many cases, stabilise — or even improve — vision.

For dry AMD: promising advances

For a long time, no treatment was available for the atrophic form. Today, therapies are available to slow the progression of the disease, and research is making great strides. This is precisely one of the missions of the Swiss Visio Retina Research Centre: to contribute to the development of new therapeutic approaches for patients with dry AMD.

Prevention: an underestimated factor

In addition to medical treatment, certain everyday habits can reduce the risk of the condition progressing:

Give up smoking
Eat a diet rich in green vegetables, fruit and oily fish (omega-3)
Take vitamin and antioxidant supplements if recommended by your doctor
Wear sunglasses to limit exposure to UV rays

Check regularly – the most important decision

The earlier AMD is detected and treated, the better the visual prognosis. An annual check-up with an ophthalmologist is recommended from the age of 50.

About the author

Dr Aude Ambresin is an ophthalmologist specialising in medical retina, based in Lausanne, Switzerland. She is Medical Director and co-founder of the RétinElysée private retina centre in Lausanne, as well as a consultant in medical retina at Swiss Visio Montchoisi. She is also a lecturer at the Faculty of Medicine, University of Lausanne.

Dr Ambresin heads a clinical trials unit dedicated to retinal diseases, with particular expertise in age-related macular degeneration (AMD). She actively incorporates new technologies and artificial intelligence into her clinical research.

Her articles have been published in leading medical journals, notably the Revue Médicale Suisse.

Hospitals

Centres

For patients

About us

Integrated care